Seco-Duocarmycin TM

Seco-Duocarmycin TM is a potent DNA-alkylating agent and an advanced ADC cytotoxin widely explored as an ADC payload in antibody-drug conjugates. Its mechanism involves selective binding to the minor groove of DNA, followed by alkylation that induces irreversible DNA damage and triggers apoptosis. This high cytotoxicity makes Seco-Duocarmycin TM a valuable component for targeted oncology therapies, particularly when precise delivery via ADCs is required.

In antibody-drug conjugates, Seco-Duocarmycin TM is typically conjugated to monoclonal antibodies through cleavable linker systems, allowing controlled release within tumor cells. The ADC remains stable in systemic circulation, preventing premature toxicity, while intracellular enzymatic cleavage liberates the active payload. This tumor-specific activation ensures maximal antitumor activity and minimizes off-target effects, highlighting its suitability as a payload in precision ADC therapeutics.

Applications of Seco-Duocarmycin TM include experimental ADCs targeting both hematologic and solid tumors, such as breast, lung, and ovarian cancers. Its potent DNA-alkylating activity allows therapeutic efficacy at low drug-to-antibody ratios (DARs), which is critical for improving safety and selectivity. Additionally, the compound’s structural versatility supports conjugation with various linker chemistries, optimizing stability, intracellular release, and overall antitumor performance in next-generation ADC development programs.